Patients' characteristics and outcome of CTL infusions
| Pt no. . | Sex . | Tx/time to PTLD . | Age at CTL, y . | Pre-Tx EBV* . | PTLD sites . | PTLD histology† . | Pre-CTL EBV DNA‡ . | Previous Rx for PTLD . | Outcome, 5 wk . | Outcome, 6 mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | Liver/3 mo | 1 | Pos | Tonsil, stomach, bowel | Monomorphic | 106 | RIS, ACV | CR | CR |
| 2 | F | Liver/6.5 y | 76 | NK | Bowel | Hodgkin | ND | RIS, surgery | CR | CR |
| 3 | M | Heart/5.5 y | 51 | NK | Orbit, pectoral | Monomorphic | 454 | RIS | CR | CR |
| 4 | F | Stem cell/1.5 mo | 30 | Pos | LN (multisites), blood | Polymorphic | ND | RIS, rituximab | CR | CR |
| 5 | M | Bone marrow/4 mo | 27 | NK | LN | Polymorphic | ND | RIS, Chemo, radio | CR | CR |
| 6 | F | Kidney/9 y | 68 | NK | LN, bone marrow | Burkitt | 24 000 | RIS, chemo | CR | CR |
| 7 | F | Kidney/19 y | 67 | NK | LN (multisites) | Hodgkin | ND | RIS | CR | CR |
| 8 | F | Liver/9 mo | 13 | Neg | Bowel, LN | Hyperplastic | ND | RIS, VCV | CR | CR |
| 9 | F | Liver/3 mo | 50 | NK | LN (multisites) | Hodgkin | ND | RIS, radio | CR | CR |
| 10 | M | Liver, small bowel/21 mo | 3 | Neg | Sigmoid colon, duodenum | Hyperplastic | 1200 | RIS | CR | CR |
| 11 | F | Liver/4.2 y | 5 | Neg | LN | Hyperplastic | 339 | RIS | CR | CR |
| 12 | M | Liver, small bowel/9 mo | 2 | Neg | Small bowel, LN | Hodgkin | 1052 | RIS, GCV | CR | CR |
| 13 | F | Kidney/23 mo | 19 | Neg | Brain (multiple) | Polymorphic | ND | RIS, rituximab, chemo, radio | PR | CR |
| 14 | F | Kidney/23 mo | 35 | Neg | Brain (multiple) | Monomorphic | ND | RIS | PR | CR |
| 15 | M | Kidney/3.5 y | 41 | Neg | Gingivae, adrenals | Monomorphic | 4000 | RIS | PR | PR |
| 16 | M | Kidney/18.5 y | 64 | NK | Kidney, bladder, LN | Monomorphic | 100 000 | RIS, chemo, radio | PR | PR |
| 17 | M | Liver/4.3 y | 60 | NK | Liver, abdomen LN | Polymorphic | 640 | RIS | PR | PR |
| 18 | M | Kidney/5.3 y | 11 | Pos | Tonsil, LN (multisites) | Polymorphic | 1.2 × 106 | RIS | PR | NR |
| 19 | M | Heart/20 y | 33 | NK | LN (multisites) | Hyperplastic | ND | RIS | PR | NR |
| 20 | M | Liver/9 y | 14 | Neg | LN (multisites) | Hodgkin | ND | RIS | PR | NR |
| 21 | F | Heart, lungs/3 y | 51 | Pos | Brain (mulitple) | Monomorphic | ND | RIS, rituximab, chemo, radio | PR | NR; died |
| 22 | M | Kidney/8 y | 61 | Pos | Large pelvic mass (kidney, bladder) | Monomorphic | 24 000 | RIS, rituximab, chemo, radio | NR | NR; died |
| 23 | M | Liver/4.7 y | 49 | NK | Blood, bone marrow | Polymorphic | ND | RIS | NR | NR |
| 24 | M | Kidney/10 y | 48 | NK | Eye, spine, bladder, LN | Monomorphic | 7900 | RIS, rituximab | NR | NR |
| 25 | M | Kidney/8.8 y | 51 | NK | LN (multisites) | Monomorphic | 50 752 | RIS | NR | NR |
| 26 | M | Kidney/13 y | 19 | NK | Brain (multiple) | Polymorphic | 3200 | RIS | NR | NR |
| 27 | M | Lung/3 mo | 8 | NK | LN (multisites) | Polymorphic | 704 | RIS, rituximab, Anti-IL6, GCV | NR | NR |
| 28 | M | Liver/8.5 y | 61 | NK | LN (multisites) | Monomorphic | 1827 | RIS | NR | NR |
| 29 | M | Kidney/6 y | 53 | NK | Lungs, LN | Polymorphic | ND | RIS, rituximab, chemo | NR; died d8 | NR; died |
| 30 | F | Lung/3 mo | 58 | Pos | Lung, LN | Monomorphic | ND | RIS, rituximab, chemo | NR–Died d11 | NR; died |
| 31 | F | Kidney/6 mo | 12 | Neg | Kidney, spleen, liver, bone marrow, pleura | Hyperplastic | 2127 | RIS, rituximab | NR; died d10 | NR; died |
| 32 | M | Liver, small bowel/21 mo | 3 | Neg | Jejunam, duodenum, sigmoid colon, rectum | Hyperplastic | ND | RIS | NR; died d25 | NR; died |
| 33 | F | Liver/4 mo | 69 | Pos | Liver allograft | Hyperplastic | ND | RIS | NR; died d10 | NR; died |
| Pt no. . | Sex . | Tx/time to PTLD . | Age at CTL, y . | Pre-Tx EBV* . | PTLD sites . | PTLD histology† . | Pre-CTL EBV DNA‡ . | Previous Rx for PTLD . | Outcome, 5 wk . | Outcome, 6 mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | Liver/3 mo | 1 | Pos | Tonsil, stomach, bowel | Monomorphic | 106 | RIS, ACV | CR | CR |
| 2 | F | Liver/6.5 y | 76 | NK | Bowel | Hodgkin | ND | RIS, surgery | CR | CR |
| 3 | M | Heart/5.5 y | 51 | NK | Orbit, pectoral | Monomorphic | 454 | RIS | CR | CR |
| 4 | F | Stem cell/1.5 mo | 30 | Pos | LN (multisites), blood | Polymorphic | ND | RIS, rituximab | CR | CR |
| 5 | M | Bone marrow/4 mo | 27 | NK | LN | Polymorphic | ND | RIS, Chemo, radio | CR | CR |
| 6 | F | Kidney/9 y | 68 | NK | LN, bone marrow | Burkitt | 24 000 | RIS, chemo | CR | CR |
| 7 | F | Kidney/19 y | 67 | NK | LN (multisites) | Hodgkin | ND | RIS | CR | CR |
| 8 | F | Liver/9 mo | 13 | Neg | Bowel, LN | Hyperplastic | ND | RIS, VCV | CR | CR |
| 9 | F | Liver/3 mo | 50 | NK | LN (multisites) | Hodgkin | ND | RIS, radio | CR | CR |
| 10 | M | Liver, small bowel/21 mo | 3 | Neg | Sigmoid colon, duodenum | Hyperplastic | 1200 | RIS | CR | CR |
| 11 | F | Liver/4.2 y | 5 | Neg | LN | Hyperplastic | 339 | RIS | CR | CR |
| 12 | M | Liver, small bowel/9 mo | 2 | Neg | Small bowel, LN | Hodgkin | 1052 | RIS, GCV | CR | CR |
| 13 | F | Kidney/23 mo | 19 | Neg | Brain (multiple) | Polymorphic | ND | RIS, rituximab, chemo, radio | PR | CR |
| 14 | F | Kidney/23 mo | 35 | Neg | Brain (multiple) | Monomorphic | ND | RIS | PR | CR |
| 15 | M | Kidney/3.5 y | 41 | Neg | Gingivae, adrenals | Monomorphic | 4000 | RIS | PR | PR |
| 16 | M | Kidney/18.5 y | 64 | NK | Kidney, bladder, LN | Monomorphic | 100 000 | RIS, chemo, radio | PR | PR |
| 17 | M | Liver/4.3 y | 60 | NK | Liver, abdomen LN | Polymorphic | 640 | RIS | PR | PR |
| 18 | M | Kidney/5.3 y | 11 | Pos | Tonsil, LN (multisites) | Polymorphic | 1.2 × 106 | RIS | PR | NR |
| 19 | M | Heart/20 y | 33 | NK | LN (multisites) | Hyperplastic | ND | RIS | PR | NR |
| 20 | M | Liver/9 y | 14 | Neg | LN (multisites) | Hodgkin | ND | RIS | PR | NR |
| 21 | F | Heart, lungs/3 y | 51 | Pos | Brain (mulitple) | Monomorphic | ND | RIS, rituximab, chemo, radio | PR | NR; died |
| 22 | M | Kidney/8 y | 61 | Pos | Large pelvic mass (kidney, bladder) | Monomorphic | 24 000 | RIS, rituximab, chemo, radio | NR | NR; died |
| 23 | M | Liver/4.7 y | 49 | NK | Blood, bone marrow | Polymorphic | ND | RIS | NR | NR |
| 24 | M | Kidney/10 y | 48 | NK | Eye, spine, bladder, LN | Monomorphic | 7900 | RIS, rituximab | NR | NR |
| 25 | M | Kidney/8.8 y | 51 | NK | LN (multisites) | Monomorphic | 50 752 | RIS | NR | NR |
| 26 | M | Kidney/13 y | 19 | NK | Brain (multiple) | Polymorphic | 3200 | RIS | NR | NR |
| 27 | M | Lung/3 mo | 8 | NK | LN (multisites) | Polymorphic | 704 | RIS, rituximab, Anti-IL6, GCV | NR | NR |
| 28 | M | Liver/8.5 y | 61 | NK | LN (multisites) | Monomorphic | 1827 | RIS | NR | NR |
| 29 | M | Kidney/6 y | 53 | NK | Lungs, LN | Polymorphic | ND | RIS, rituximab, chemo | NR; died d8 | NR; died |
| 30 | F | Lung/3 mo | 58 | Pos | Lung, LN | Monomorphic | ND | RIS, rituximab, chemo | NR–Died d11 | NR; died |
| 31 | F | Kidney/6 mo | 12 | Neg | Kidney, spleen, liver, bone marrow, pleura | Hyperplastic | 2127 | RIS, rituximab | NR; died d10 | NR; died |
| 32 | M | Liver, small bowel/21 mo | 3 | Neg | Jejunam, duodenum, sigmoid colon, rectum | Hyperplastic | ND | RIS | NR; died d25 | NR; died |
| 33 | F | Liver/4 mo | 69 | Pos | Liver allograft | Hyperplastic | ND | RIS | NR; died d10 | NR; died |
Pt indicates patient; Tx, transplantation; y, years; Rx, treatment; F, female; wk, weeks; mo, months; Pos, positive; RIS, reduction of immunosuppression; ACV, aciclovir; CR, complete response; NK, not known; ND, not detected; M, male; LN, lymph nodes; chemo, chemotherapy; radio, radiotherapy; Neg, negative; VCV, valaciclovir; GCV, ganciclovir; PR, partial response; and NR, no response.
Serum anti-VCA IgG.
All PTLD tumor biopsies were positive for EBERs by in situ hybridization.
Copies of EBV DNA per 106 PBMCs.